Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Lymphoma, Melanoma, Ovary Cancer, Pancreas Cancer, Prostate Cancer, Solid Tumor
Conditions
Brief summary
The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients
Detailed description
The purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. Approximately 15,000 participants will take part in the greater MOHCCN study across Canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.
Interventions
None listed
Sponsors
University Health Network, Toronto
Princess Margaret Hospital, Canada
Ontario Institute for Cancer Research
Terry Fox Research Institute
Queen's University, Kingston, Ontario
Ottawa Hospital Research Institute
Kingston Health Sciences Centre
Windsor Regional Hospital
University of Windsor
London Health Sciences Centre
London Health Sciences Centre Research Institute
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy 2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through: 1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1) 2. Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization 3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling. 4. Participating patients must agree to share their anonymized clinical and genomic data
Exclusion criteria
None.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data | 5 years | Consolidate and annotate data from patients included in a pan-Canadian cohort |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases | 5 years | Improve the cancer research paradigm by bringing teams or researchers together and leverage valuable information genomic and clinical data from Canadian cancer cases. |
| Clinical effectiveness and cost-effectiveness of precision cancer medicine to advance clinical implementation and reimbursement decisions | 5 years | Health technology assessment tools will be used to evaluate the real-world value of precision medicine |
| Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine | 5 years | Health technology assessment tools will be used to evaluate the real-world value of precision medicine |
Countries
Canada
Contacts
CONTACTPM2C Central Office
PRINCIPAL_INVESTIGATORLillian Siu, MD
University Health Network, Toronto
Outcome results
None listed